Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 200 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $53.544 million which beat the analyst consensus estimate of $51.668 million by 3.63 percent. This is a 6.61 percent decrease over sales of $57.336 million the same period last year.